Lupin soars on receiving USFDA’s nod for Zileuton Extended-Release Tablets

11 Nov 2019 Evaluate

Lupin is currently trading at Rs. 732.00, up by 13.55 points or 1.89%, from its previous closing of Rs. 718.45 on the BSE.

The scrip opened at Rs. 720.05 and has touched a high and low of Rs. 733.50 and Rs. 720.05 respectively. So far 23015 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 905.90 on 04-Dec-2018 and a 52 week low of Rs. 646.20 on 07-Oct-2019.

Last one week high and low of the scrip stood at Rs. 786.75 and Rs. 715.90 respectively. The current market cap of the company is Rs. 33133.40 crore.

The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.99% and 14.05% respectively.

Lupin has received approval for its Zileuton Extended-Release Tablets, 600 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Zyflo CR Extended-Release Tablets, 600 mg, of Chiesi USA, Inc.

Lupin's Zileuton Extended-Release Tablets, 600 mg are indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileuton Extended-Release Tablets, 600 mg had annual sales of approximately $43 million in the US. (IQVIA MAT September 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

1613.15 18.25 (1.14%)
26-Apr-2024 14:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1503.70
Dr. Reddys Lab 6285.80
Cipla 1409.20
Zydus Lifesciences 948.55
Lupin 1613.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.